Side-Effects of Anti-Inflammatory Drugs 3 [electronic resource] / edited by K.D. Rainsford, G.P. Velo.
This book brings together physicians, scientists and those concerned with the production and use of anti-inflammatory drugs to discuss basic issues affecting all aspects of side-effects, including their detection and treatment. <br/> The chapters cover a wide variety of topics including the ep...
Saved in:
| Online Access: |
Full Text (via Springer) |
|---|---|
| Main Author: | |
| Other Authors: | |
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Dordrecht :
Springer Netherlands : Imprint : Springer,
1992.
|
| Series: | Inflammation and drug therapy series ;
5. |
| Subjects: |
Table of Contents:
- Section I: Epidemiology
- 1 The gastrointestinal toxicity of the non-steroidal anti-inflammatory drugs
- 2 The value of the case-control approach for the evaluation of the risk of upper gastrointestinal bleeding associated with the previous use of non-steroidal anti-inflammatory drugs
- 3 Liver toxicity of antipyretic drugs in conjunction with measles infections
- 4 Non-steroidal anti-inflammatory drugs and hypersensitivity reactions
- 5 What can a spontaneous reporting system teach about side-effects of anti-inflammatory drugs?
- 6 Adverse reactions to NSAIDs: consecutive evaluation of 30 000 patients in rheumatology
- Section II: Gastrointestinal Tract: Clinical Aspects
- 7 The evaluation of acute gastrointestinal toxicity of NSAIDs in phase I clinical trials: a critical appraisal
- 8 The ulcerogenic and anti-haemostatic effects of NSAIDs in the gut
- 9 What role does Helicobacter pylori infection play in NSAID-associated gastric inflammation?
- 10 Endoscopic evaluation of NSAID ulceration
- 11 Food antigen absorption in rheumatoid arthritis: effect of acetylsalicylic acid
- 12 Intestinal mucosal permeability in inflammatory rheumatic diseases
- 13 Comparison of effects on gastrointestinal blood loss and gastric mucosal appearance of piroxicam-?-cyclodextrin, piroxicam and placebo
- Section III: Gastrointestinal Tract: Prevention Of Adverse Effects
- 14 Mechanisms of gastrointestinal ulceration from non-steroidal anti-inflammatory drugs: a basis for use and development of protective agents
- 15 Novel strategies of gastric and duodenal mucosal protection against NSAID injury: role of protease inhibitors, muscle relaxants and growth factors
- 16 The role of misoprostol in preventing NSAID-induced damage to the gastrointestinal tract
- 17 Possible factors involved in the protective effects of interleukin-1 in aspirin- and indomethacin-induced gastric damage
- 18 Prevention and treatment of NSAID-gastroduodenal damage: the role of H2-receptor antagonists
- 19 Omeprazole in the prevention and therapy of gastroduodenal lesions on NSAID therapy
- 20 Sucralfate in the prevention of NSAID-induced gastric ulceration
- 21 Ketotifen
- a novel approach to the prevention of damage in the gastrointestinal tract
- Section IV: Hepatotoxicity
- 22 The hepatotoxicity of non-steroidal anti-inflammatory drugs
- 23 Paracetamol (acetaminophen) bioactivation by liver microsomes
- its role in hepatotoxicity
- 24 Increased liver toxicity of diclofenac by paracetamol: results and possible mechanisms
- 25 Effects of NSAIDs on liver microsomal mono-oxygenase system and products of oxidative metabolism of arachidonic acid
- 26 Hepatitis due to non-steroidal anti-inflammatory drugs (NSAIDs)
- Section V: Nephrotoxicity
- 27 Current status of nephrotoxicity caused by non-steroidal anti-inflammatory drugs
- 28 Are oral prostaglandins effective in preventing nephrotoxicity from NSAIDs and cyclosporin?
- Section VI: Specific Issues Related To Side-Effects
- 29 Aspirin and Reye's syndrome
- 30 Antirheumatic drug therapy in the elderly
- 31 NSAIDs and human cartilage metabolism
- 32 Non-steroidal anti-inflammatory drugs and the augmented lipoxygenase pathway: conceivable impact on joint conditions
- 33 Therapeutic potential of 5-lipoxygenase inhibitors: the discovery and development of MK-886, a novelmechanism leukotriene inhibitor
- 34 Mechanisms of rash formation and related skin conditions induced by non-steroidal anti-inflammatory drugs
- Section VII: Antirheumatic And Immunoregulatory Agents
- 35 Cyclosporin: clinical efficacy and toxicity in patients with rheumatoid arthritis
- 36 Risk factors and risk-benefit problems in the use of DMARDs
- 37 Gold toxicity: chemical, structural, biological and clinical experimental issues
- Section VIII: Extended Poster Presentations
- 38 A review of interaction studies between non-steroidal anti-inflammatory drugs and HTreceptor antagonists or prostaglandin analogues
- 39 Influence of different anti-inflammatory substances on ethanol- and indomethacin-induced gastrointestinal mucosal damage
- 40 The role of copper in preventing gastric damage by acetylsalicylic acid
- 41 Effect of NSAID therapy on plasma, whole blood cell (BC), and 24h urine zinc in patients with rheumatoid arthritis (RA).